Akihiro Yoshimura

1.3k total citations
44 papers, 461 citations indexed

About

Akihiro Yoshimura is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Akihiro Yoshimura has authored 44 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Akihiro Yoshimura's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Akihiro Yoshimura is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Akihiro Yoshimura collaborates with scholars based in Japan and United Kingdom. Akihiro Yoshimura's co-authors include Koichi Takayama, Tadaaki Yamada, Junji Uchino, Yusuke Chihara, Yoshiko Kaneko, Nobuyo Tamiya, Shinsuke Shiotsu, Keiko Tanimura, Yuki Katayama and Tatsuya Imabayashi and has published in prestigious journals such as Journal of Lipid Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Akihiro Yoshimura

43 papers receiving 458 citations

Peers

Akihiro Yoshimura
Natalia Glatzel-Plucińska Poland
Fadel Bennani Ireland
Xiao Zhou China
Nanya Wang China
Ashley J. Williamson United States
Tuo Deng China
Timothy Yen United States
Natalia Glatzel-Plucińska Poland
Akihiro Yoshimura
Citations per year, relative to Akihiro Yoshimura Akihiro Yoshimura (= 1×) peers Natalia Glatzel-Plucińska

Countries citing papers authored by Akihiro Yoshimura

Since Specialization
Citations

This map shows the geographic impact of Akihiro Yoshimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Yoshimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Yoshimura more than expected).

Fields of papers citing papers by Akihiro Yoshimura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihiro Yoshimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Yoshimura. The network helps show where Akihiro Yoshimura may publish in the future.

Co-authorship network of co-authors of Akihiro Yoshimura

This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Yoshimura. A scholar is included among the top collaborators of Akihiro Yoshimura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Yoshimura. Akihiro Yoshimura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horinaka, Mano, et al.. (2025). Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer. Molecular Cancer Therapeutics. 24(10). 1537–1545. 2 indexed citations
2.
Yoshimura, Akihiro, Mano Horinaka, Takeshi Yaoi, et al.. (2024). Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British Journal of Cancer. 131(2). 361–371. 9 indexed citations
3.
4.
Nakagawa, Tomoyuki, et al.. (2024). Japanese sake making using wild yeasts isolated from natural environments. Bioscience Biotechnology and Biochemistry. 88(3). 231–236. 2 indexed citations
5.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2023). TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100494–100494. 5 indexed citations
6.
7.
Kawachi, Hayato, Tadaaki Yamada, Akihiro Yoshimura, et al.. (2023). Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study). Therapeutic Advances in Medical Oncology. 15. 2621758–2621758. 1 indexed citations
8.
9.
Yamada, Tadaaki, Satomi Tanaka, Shinsuke Shiotsu, et al.. (2023). Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer. Cancer Medicine. 12(8). 9097–9105. 4 indexed citations
10.
11.
Taniguchi, Yoshihiko, Tadaaki Yamada, Akihiro Yoshimura, et al.. (2020). 411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation. Annals of Oncology. 31. S1402–S1403. 1 indexed citations
12.
Yamada, Tadaaki, Yuki Katayama, Akihiro Yoshimura, et al.. (2019). Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer. Cancer Medicine. 8(4). 1521–1529. 78 indexed citations
13.
Imabayashi, Tatsuya, Junji Uchino, Akihiro Yoshimura, et al.. (2019). Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers. 11(3). 410–410. 31 indexed citations
14.
Katayama, Yuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2019). Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer. Thoracic Cancer. 10(3). 526–532. 16 indexed citations
15.
Nishioka, Naoya, Junji Uchino, Yuki Katayama, et al.. (2019). Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 8(4). 450–450. 75 indexed citations
16.
Yoshimura, Akihiro, Tadaaki Yamada, Taisuke Tsuji, et al.. (2019). Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis. Thoracic Cancer. 10(3). 557–563. 8 indexed citations
17.
Yoshimura, Akihiro, Tadaaki Yamada, Takayuki Takeda, et al.. (2019). Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers. 11(3). 365–365. 11 indexed citations
18.
Yoshimura, Akihiro, Tadaaki Yamada, Aya Miyagawa‐Hayashino, et al.. (2019). Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer. 137. 108–112. 10 indexed citations
19.
Nakagawa, Tomoyuki, Akihiro Yoshimura, Hisanori Tamaki, et al.. (2019). Identification and <i>Sake</i>-Brewing Characteristics of Yeast Strains Isolated from Natural Environments in Gifu. JOURNAL OF THE BREWING SOCIETY OF JAPAN. 114(1). 43–52. 5 indexed citations
20.
Yoshimura, Akihiro, et al.. (2018). Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. Clinical Case Reports. 6(7). 1338–1341. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natalia Glatzel-Plucińska Breakdown of academic impact, for papers by Fadel Bennani Breakdown of academic impact, for papers by Xiao Zhou Breakdown of academic impact, for papers by Nanya Wang Breakdown of academic impact, for papers by Ashley J. Williamson Breakdown of academic impact, for papers by Tuo Deng Breakdown of academic impact, for papers by Timothy Yen
Rankless by CCL
2026